Sentence examples for benchmark when compared with from inspiring English sources

"Turkey's democracy may be a good benchmark when compared with Egypt, Libya or Syria," said Hakan Altinay, a senior fellow at the Brookings Institution.

The SAT-based multi-pin net dogleg-free formulations presented here achieve significant improvement over existing SAT-based solutions with respect to the number of variables and clauses used, thereby achieving greater scalability and also display comparable and sometimes better routability results on benchmark circuits when compared with other detailed routing solutions.

These probabilistic models provide estimates for the variance and credibility interval for each transcript and generate more accurate estimates of low levels of gene expression on benchmark datasets when compared with other stochastic models (Text S1).

Results in Figure 21 indicate that the increase in clock frequency required to achieve a shorter execution time to match performance with software bypassing leads to an increase in energy consumption for four of the eight benchmarks, when compared to the fully connected architecture with bypassing synthesized for 250 MHz.

When compared with benchmark delivery compounds, the peptides are shown to have low toxicity and are highly effective at mediating gene silencing in adherent MCF-7 and A549 cell lines, primary human umbilical vein endothelial cells and both differentiated macrophage-like and suspension monocyte-like THP-1 cells.

Finally, our time-varying non-linear formulations yield reasonably good predictions when compared with the benchmark experimental results available in the literature.

It should be noted that in most cases MUSTANG-MR alignment at some sieving level would yield lower Q scores than the unsieved (initial) alignment when compared with SISYPHUS benchmark.

The use of overlap areas also resulted in a greater difference between case and control landscapes, when compared with the benchmark (using the full buffer area).

Findings are quite interesting as the control groups of non-SDD studies had similar rates of VAP when compared with the benchmark (17.5 versus 22 out of 100 patients), but the control groups from the SDD studies had a higher rate of VAPs than the benchmark (42 versus 22 out of 100 patients) [ 55].

Our study revealed that metronomic etoposide plus bevacizumab has encouraging outcome when compared with established benchmarks.

NICAD having claimed to have obtained 100% when compared with Bellon's benchmark results, which concludes that the proposed method has also accomplished the same output.